Esperion Rises as Cholesterol Drug Can Forgo Heart Trial
This article is for subscribers only.
Esperion Therapeutics Inc. said U.S. regulators won’t require a trial to determine the effects of its experimental cholesterol drug on heart health, smoothing the path toward approval.
Shares of the biotech company gained 11 percent in extended trading in New York. They had risen 14 percent to close at $75.51 earlier, before the news was announced.